As the development of diabetes in NOD mice depends on the production of IFN-γ from CD4+ T cells [30], and IFN-γ production and IL-17 production is elevated in islet-reactive CD4+ T cells in recent onset type 1 diabetes patients [5, 31], we hypothesised that administration of IC87114 could have beneficial effects on anti-islet inflammation and be a feasible option of type 1 diabetes therapy. This evidence concerns the gene IL17A and diabetes mellitus.